Fbxw7 in cell cycle exit and stem cell maintenance: Insight from gene-targeted mice

Cell Cycle

Volumn 7, Issue 21, 2008, Pages 3307-3313

  Onoyama, Ichiro ^b   Nakayama, Keiichi I ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NONE

Author keywords

Cell cycle; F box protein; Knockout mouse; Protein degradation; SCF complex; Ubiquitin

Indexed keywords

CYCLIN E; DNA 26S; F BOX PROTEIN; MYC PROTEIN; NOTCH RECEPTOR; PROTEASOME; PROTEIN C JUN; PROTEIN P53; UBIQUITIN PROTEIN LIGASE;

APOPTOSIS; CANCER CONTROL; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL RENEWAL; EMBRYO CELL; EMBRYONIC STEM CELL; FBXW7 GENE; FIBROBLAST; GENE; GENE DELETION; GENE MUTATION; HEMATOPOIETIC STEM CELL; NONHUMAN; PHENOTYPE; PLEIOTROPY; PROTEIN DEGRADATION; PROTEIN INDUCTION; REVIEW; STEM CELL; T LYMPHOCYTE; THYMOCYTE; TISSUE REACTION; UBIQUITINATION;

ANIMALIA; MUS;

EID: 55849100682     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.21.6931     Document Type: Review

References (53)

1. Nakayama KI, Nakayama K. Ubiquitin ligases: cell cycle control and cancer. Nat Rev Cancer 2006; 6:369-81.
2. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer. Nat Rev Cancer 2008; 8:438-49.
3. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 2008; 8:83-93.
4. Moberg KH, Bell DW, Wahrer DC, Haber DA, Hariharan IK. Archipelago regulates cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature 2001; 413:311-6.
5. Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 2001; 413:316-22.
6. Fbw7 ubiquitin ligase. Science 2001; 294:173-7.
7. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K, Nakayama KI. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 2004; 23:2116-25.
8. Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN, Clurman BE. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci USA 2004; 101:9085-90.
9. Hubbard EJ, Wu G, Kitajewski J, Greenwald I. sel-10, a negative regulator of lin-12 activity in Caenorhabditis elegans, encodes a member of the CDC4 family of proteins. Genes Dev 1997; 11:3182-93.
10. Gupta-Rossi N, Le Bail O, Gonen H, Brou C, Logeat F, Six E, Ciechanover A, Israel A. Functional interaction between SEL-10, an F-box protein, and the nuclear form of activated Notch1 receptor. J Biol Chem 2001; 276:34371-8.
11. Oberg C, Li J, Pauley A, Wolf E, Gurney M, Lendahl U. The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog. J Biol Chem 2001; 276:35847-53.
12. Wu G, Lyapina S, Das I, Li J, Gurney M, Pauley A, Chui I, Deshaies RJ, Kitajewski J. SEL-10 is an inhibitor of notch signaling that targets notch for ubiquitin-mediated protein degradation. Mol Cell Biol 2001; 21:7403-15.
13. Fbw7 antagonizes apoptotic JNK signaling. Science 2004; 303:1374-8.
14. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999; 1:193-9.
15. Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1999; 1:207-14.
16. Skp2 complex through phosphorylated Thr187 in p27. Curr Biol 1999; 9:661-4.
17. CIP1/WAF1 and cyclin D proteins. Proc Natl Acad Sci USA 1998; 95:11324-9.
18. Cip1 in S phase. J Biol Chem 2003; 278:25752-7.
19. Skp2-dependent ubiquitylation. Proc Natl Acad Sci USA 2003; 100:10231-6.
20. Skp2. Genes Dev 2002; 16:2946-57.
21. Bhattacharya S, Garriga J, Calbo J, Yong T, Haines DS, Grana X. SKP2 associates with p130 and accelerates p130 ubiquitylation and degradation in human cells. Oncogene 2003; 22:2443-51.
22. 1 phase. Nat Cell Biol 2004; 6:1229-35.
23. 1 phase. J Biol Chem 2005; 280:17694-700.
24. 1 phase of the cell cycle. Mol Cell Biol 2005; 25:9292-303.
25. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996; 85:707-20.
26. Kip1. Cell 1996; 85:721-32.
27. Kip1-deficient mice. Cell 1996; 85:733-44.
28. Kip1, polyploidy and centrosome overduplication. EMBO J 2000; 19:2069-81.
29. Nakayama K, Nagahama H, Minamishima YA, Miyake S, Ishida N, Hatakeyama S, Kitagawa M, Iemura S, Natsume T, Nakayama KI. Skp2-mediated degradation of p27 regulates progression into mitosis. Dev Cell 2004; 6:661-72.
30. kip1 is essential for cell cycle progression. Genes Dev 2004; 18:2602-7.
31. Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 2003; 13:41-7.
32. Nakayama KI, Nakayama K. Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin Cell Dev Biol 2005; 16:323-33.
33. Eilers M, Schirm S, Bishop JM. The MYC protein activates transcription of the alpha-prothymosin gene. EMBO J 1991; 10:133-41.
34. Blackwood EM, Kretzner L, Eisenman RN. Myc and Max function as a nucleoprotein complex. Curr Opin Genet Dev 1992; 2:227-35.
35. Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, Protopopov A, O'Neil J, Gutierrez A, Ivanova E, Perna I, Lin E, Mani V, Jiang S, McNamara K, Zaghlul S, Edkins S, Stevens C, Brennan C, Martin ES, Wiedemeyer R, Kabbarah O, Nogueira C, Histen G, Aster J, Mansour M, Duke V, Foroni L, Fielding AK, Goldstone AH, Rowe JM, Wang YA, Look AT, Stratton MR, Chin L, Futreal PA, DePinho RA. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 2007; 447:966-71.
36. Lee JW, Soung YH, Kim HJ, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH. Mutational analysis of the hCDC4 gene in gastric carcinomas. Eur J Cancer 2006; 42:2369-73.
37. Kemp Z, Rowan A, Chambers W, Wortham N, Halford S, Sieber O, Mortensen N, von Herbay A, Gunther T, Ilyas M, Tomlinson I. CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instability. Cancer Res 2005; 65:11361-6.
38. Hubalek MM, Widschwendter A, Erdel M, Gschwendtner A, Fiegl HM, Muller HM, Goebel G, Mueller-Holzner E, Marth C, Spruck CH, Reed SI, Widschwendter M. Cyclin E dysregulation and chromosomal instability in endometrial cancer. Oncogene 2004; 23:4187-92.
39. Koh MS, Ittmann M, Kadmon D, Thompson TC, Leach FS. CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer. Cancer Biol Ther 2006; 5:78-83.
40. Calhoun ES, Jones JB, Ashfaq R, Adsay V, Baker SJ, Valentine V, Hempen PM, Hilgers W, Yeo CJ, Hruban RH, Kern SE. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol 2003; 163:1255-60.
41. Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D, Marth C, Mueller-Holzner E, Corcoran M, Dagnell M, Nejad SZ, Nayer BN, Zali MR, Hansson J, Egyhazi S, Petersson F, Sangfelt P, Nordgren H, Grander D, Reed SI, Widschwendter M, Sangfelt O, Spruck C. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 2007; 67:9006-12.
42. Song JH, Schnittke N, Zaat A, Walsh CS, Miller CW. FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias. Leuk Res 2008; 32:1751-5.
43. FBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med 2007; 204:1825-35.
44. O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C, Hardwick J, Welcker M, Meijerink JP, Pieters R, Draetta G, Sears R, Clurman BE, Look AT. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors. J Exp Med 2007; 204:1813-24.
45. Malyukova A, Dohda T, von der Lehr N, Akhoondi S, Corcoran M, Heyman M, Spruck C, Grander D, Lendahl U, Sangfelt O. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res 2007; 67:5611-6.
46. Tsunematsu R, Nakayama K, Oike Y, Nishiyama M, Ishida N, Hatakeyama S, Bessho Y, Kageyama R, Suda T, Nakayama KI. Mouse Fbw7/Sel-10/Cdc4 is required for notch degradation during vascular development. J Biol Chem 2004; 279:9417-23.
47. Tetzlaff MT, Yu W, Li M, Zhang P, Finegold M, Mahon K, Harper JW, Schwartz RJ, Elledge SJ. Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein. Proc Natl Acad Sci USA 2004; 101:3338-45.
48. Onoyama I, Tsunematsu R, Matsumoto A, Kimura T, de Alboran IM, Nakayama K, Nakayama KI. Conditional inactivation of Fbxw7 impairs cell cycle exit during T cell differentiation and results in lymphomatogenesis. J Exp Med 2007; 204:2875-88.
49. Matsuoka S, Oike Y, Onoyama I, Iwama A, Arai F, Takubo K, Mashimo Y, Oguro H, Nitta E, Ito K, Miyamoto K, Yoshiwara H, Hosokawa K, Nakamura Y, Gomei Y, Iwasaki H, Hayashi Y, Matsuzaki Y, Nakayama K, Ikeda Y, Hata A, Chiba S, Nakayama KI, Suda T. Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev 2008; 22:986-91.
50. Ishikawa Y, Onoyama I, Nakayama KI, Nakayama K. Notch-dependent cell cycle arrest and apoptosis in mouse embryonic fibroblasts lacking Fbxw7. Oncogene 2008.
51. Matsumoto A, Onoyama I, Nakayama KI. Expression of mouse Fbxw7 isoforms is regulated in a cell cycle- or p53-dependent manner. Biochem Biophys Res Commun 2006; 350:114-9.
52. Wilson A, Murphy MJ, Oskarsson T, Kaloulis K, Bettess MD, Oser GM, Pasche AC, Knabenhans C, Macdonald HR, Trumpp A. c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev 2004; 18:2747-63.
53. Thompson BJ, Jankovic V, Gao J, Buonamici S, Vest A, Lee JM, Zavadil J, Nimer SD, Aifantis I. Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. J Exp Med 2008; 205:1395-408.